PTJ
LYEL icon

Paul Tudor Jones’s Lyell Immunopharma LYEL Stock Holding History

Paul Tudor Jones’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,216
Closed -$66.9K – 3549
2025
Q1 		$66.9K Hold
6,216
– – ﹤0.01% 2948
2024
Q4 		$79.6K Hold
6,216
– – ﹤0.01% 2915
2024
Q3 		$172K Hold
6,216
– – ﹤0.01% 2558
2024
Q2 		$180K Buy
6,216
+1,916
+45% +$91.2K ﹤0.01% 2168
2024
Q1 		$192K Buy
+4,300
New +$184K ﹤0.01% 2047
2023
Q1 		– Sell
-6,240
Closed -$433K – 2731
2022
Q4 		$433K Buy
+6,240
New +$620K 0.01% 1679
2021
Q3 		– Sell
-598
Closed -$194K – 2657
2021
Q2 		$194K Buy
+598
New +$196K ﹤0.01% 1501

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Paul Tudor Jones's LYEL Position: Q2 2025 in Review

Paul Tudor Jones sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 6,216 shares — an estimated $66.9K sold.

Paul Tudor Jones first reported a position in LYEL in Q2 2021 and held it in 7 quarters. The position peaked at $433K in Q4 2022. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Paul Tudor Jones reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Paul Tudor Jones sold 6,216 Lyell Immunopharma shares in Q2 2025, an estimated $66.9K.
  • Paul Tudor Jones first reported a position in Lyell Immunopharma in Q2 2021 and held it in 7 quarters.
  • Paul Tudor Jones's Lyell Immunopharma position peaked at $433K in Q4 2022.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Tudor Investment Corp's 13F filing for Q2 2025, filed 14 Aug 2025.